酒石酸美托洛尔联合归脾汤口服治疗颈心综合征的临床观察  

Clinical Observation of Taking Metoprolol Tartrate Combined with Guipi Decoction by Mouth on Cervical-cardiac Syndrome

作　　者：孟爱霞[1] 刘艳伟[2] 邹丽英[1] 段雪光[1] 张学红[1] 缪希红[1] MENG Aixia(The Central Hospital of Chengde,Hebei Chengde 067000,China)

机构地区：[1]河北省承德市中心医院,河北承德067000 [2]承德医学院附属医院,河北承德067000

出　　处：《河北医学》2018年第10期1680-1683,共4页Hebei Medicine

基　　金：河北省承德市科技支撑项目;(编号:20151001)

摘　　要：目的:观察酒石酸美托洛尔联合归脾汤口服治疗颈心综合征的疗效及安全性。方法:将2016年6月至2018年1月收治的78例颈心综合征患者,按照随机数字表法分为治疗组和对照组,每组各39例。对照组采用归脾汤治疗,治疗组在对照组基础上加用美托洛尔口服,以4周为1个疗程,观察各组患者早搏次数变化及SF-36生活质量评分变化,并记录两组患者是否有不良反应。结果:治疗后,两组患者早搏次数均较治疗前减少,生活质量SF-36评分均高于治疗前,差异均有统计学意义(P<0.05),且治疗组治疗后在早搏次数减少和生活质量SF-36评分升高方面均优于对照组,差异有统计学意义(P<0.05)。结论:美托洛尔联合归脾汤口服能减少颈心综合征患者的早搏次数,改善患者生活质量,且无明显不良反应。Objective:To observe the clinical effect of taking metoprolol tartrate combined with Guipi decoction by mouth in treating Cervical-cardiac Syndrome.Methods:Choose 78 cases of Cervical-cardiac Syndrome who seeing a doctor in our department from Jun 2016 to Jan 2018.And divided them into treatment group and control group according to random number table.39 cases in each group.The treatment group was treated by metoprolol tartrate combined with Guipi decoction,while the control group was treated by Guipi decoction only.4 weeks was a course of treatment.Then appraise the change of bearing premature and SF-36 quality of life score.And record the complications on course of the treatment.Results:After treatment,the bearing premature are decreased and the SF-36 quality of life score is higher than pretherapy in the two groups.the treatment group and control group all have statistical significance(P<0.05),and the treatment group is better than the control group.Possess the statistical significance(P<0.05).Conclusion:The method of taking metoprolol tartrate combined with Guipi decoction by mouth can decrease the frequency of bearing premature and improve the quality of life in Cervical-cardiac Syndrome patients.And have no obvious adverse reaction.

关 键 词：美托洛尔 归脾汤 颈心综合征 SF-36 

分 类 号：R54[医药卫生—心血管疾病] R681.55[医药卫生—内科学]